Actavis and Valeant will shrink eventually

Discussion in 'Valeant Pharmaceuticals' started by Anonymous, Nov 19, 2014 at 3:11 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    This acquisition game is a short term event in the industry due to low interest rates. Both Actavis and Valeant are now about as big as they can get with the debt loads they hold. Short of laying off half the company (again) I do not see how they will make significant money in the future.

    Actavis if they support some R&D in Allergan may have a future. Valent who knows. The last I heard they want to sell pharmaceuticals to pet owners. Maybe they should buy Petco or the old Pets.com.

    Lots of money to make elsewhere in the market. Best to leave these high risk, high rollers to the Las Vegas bookies.
     

  2. Anonymous

    Anonymous Guest

    the problem is the rest of "big pharma" are also lousy investments. a few biotechs are good but high risk